__NUXT_JSONP__("/drugs/Yttrium_Y-90_Tacatuzumab_Tetraxetan", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"476413-07-7",chebiId:"",chemicalFormula:"C16H25N5O7.Y",definition:"A radioimmunoconjugate comprised of the humanized monoclonal antibody tacatuzumab, directed against alpha fetoprotein, that is conjugated to the chelating agent tetraxetan and radiolabeled with the beta-emitting radioisotope Yttrium Y 90. Yttrium Y 90 tacatuzumab tetraxetan binds to tumor cells expressing alpha fetoprotein, thereby selectively delivering a cytotoxic dose of beta radiation.",fdaUniiCode:"GJ2416WK6Y",identifier:"C48428",preferredName:b,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129819","C1511"],synonyms:["AFP-Cide","Y-90 hAFP-31","YTTRIUM Y-90 TACATUZUMAB TETRAXETAN","Yttrium (90Y) Tacatuzumab Tetraxetan","Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31","Yttrium Y 90 Tacatuzumab Tetraxetan",b,"yttrium Y 90 DOTA monoclonal antibody HuAFP31"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FYttrium_Y-90_Tacatuzumab_Tetraxetan",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Yttrium_Y-90_Tacatuzumab_Tetraxetan","Yttrium Y-90 Tacatuzumab Tetraxetan","2021-10-30T13:40:15.133Z")));